Tolerability of palbociclib in younger and older patients with advanced breast cancer
| العنوان: | Tolerability of palbociclib in younger and older patients with advanced breast cancer |
|---|---|
| المؤلفون: | Ryan Kemper, Allison M. Deal, Kelly Brunk, Taylor Dennison, Hillary M. Heiling, Aimee Faso, Daniel J. Crona |
| المصدر: | Journal of Oncology Pharmacy Practice. 29:96-104 |
| بيانات النشر: | SAGE Publications, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, business.industry, Kinase, Advanced breast, Cancer, Palbociclib, Neutropenia, medicine.disease, Tolerability, Older patients, Internal medicine, medicine, Pharmacology (medical), business, Hormone |
| الوصف: | Introduction Palbociclib is a small-molecule cyclin-dependent kinase 4/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Patient-specific factors impacting dose reductions or discontinuations are unknown. Methods The primary objective was to evaluate the association of age (Results Among the 107 patients included, younger patients were less likely than older patients to have a palbociclib starting dose Conclusions Age ( |
| تدمد: | 1477-092X 1078-1552 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bfd7124711109dfa9a43710558bbd8 https://doi.org/10.1177/10781552211053639 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....77bfd7124711109dfa9a43710558bbd8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477092X 10781552 |
|---|